Have a personal or library account? Click to login
Implication of VDR rs7975232 and FCGR2A rs1801274 gene polymorphisms in the risk and the prognosis of 
autoimmune thyroid diseases in the Tunisian population Cover

Implication of VDR rs7975232 and FCGR2A rs1801274 gene polymorphisms in the risk and the prognosis of  autoimmune thyroid diseases in the Tunisian population

By: S Mestiri,  I Zaaber,  I Nasr and  H Marmouch  
Open Access
|Aug 2020

Figures & Tables

Figure 1

Vitamin D receptor rs7975232 polymorphism analysis. Lane M: molecular weight marker (100 bp DNA Ladder); Lane 1: homozygote (C/C); lanes 2 and 3: heterozygotes (C/A); lanes 4 and 5: homozygotes (A/A).
Vitamin D receptor rs7975232 polymorphism analysis. Lane M: molecular weight marker (100 bp DNA Ladder); Lane 1: homozygote (C/C); lanes 2 and 3: heterozygotes (C/A); lanes 4 and 5: homozygotes (A/A).

Figure 2

The FCGR2A rs1801274 polymorphism analysis. Lane M: molecular weight marker (100 bp DNA ladder); lane N: negative control; lanes P1 : patient 1, heterozygote (R/H); lanes P2: patient 2, homozygote (H/H); lanes P3 and P4: patients 3 and 4, homozygotes (R/R).
The FCGR2A rs1801274 polymorphism analysis. Lane M: molecular weight marker (100 bp DNA ladder); lane N: negative control; lanes P1 : patient 1, heterozygote (R/H); lanes P2: patient 2, homozygote (H/H); lanes P3 and P4: patients 3 and 4, homozygotes (R/R).

Distribution of VDR rs7975232 polymorphism genotypes and alleles in healthy control (n = 162), in autoimmune thyroid disease patients AITD patients (n = 162), Hashimoto’s thyroiditis patients (n = 106) and Graves’ disease patients (n = 56)_

ControlsAITD PatientsHT PatientsGD Patients
Genotypes/ Allelesn(%)n(%)p(𝜒2)OR (95% CI)n(%)p(𝜒2)OR (95% CI)n(%)p(𝜒2)OR (95% CI)
CC58(35.8)49(30.2)reference30 (28.3)reference19(33.9)reference
CA68(42.0)69(42.6)0.56(0.33)1.20(0.72-1.99)49 (46.2)0.32(0.97)1.39(0.78-2.47)20(35.7)0.91 (0.01)0.89(0.43-1.84)
AA36(22.2)44(27.2)0.27(1.20)1.44(0.80-2.58)27(25.5)0.35(0.85)1.45 (0.74-2.82)17(30.4)0.46(0.52)1.44(0.66-3.12)
CA+AA

Dominant model.

104(64.2)113 (69.8)0.34(0.89)1.28(0.80-2.04)76 (71.7)0.25(1.31)1.41 (0.83-2.40)37(66.1)0.92(0.008)1.08(0.57-2.05)
C184(56.8)167(51.5)reference109 (51.4)reference58(51.8)reference
A140(43.2)157(48.5)0.20(1.59)1.23 (0.90-1.68)103 (48.6)0.25(1.28)1.24(0.87-1.75)54(48.2)0.41 (0.65)1.22(0.79-1.88)

Hormone levels among the VDR and the FCGR2A genotypes in Hashimoto’s thyroiditis and Graves’ disease patients_

HT PatientsGD Patients
VDR rs7975232TSH

The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L.

PT4

The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L.

PTSH

The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L.

PT4

The range of normal values for TSH is 0.15-5.0 mIU/L and for T4 is 8.6-25.0 pmol/L.

P
CC56.1±105.89.5±7.60.10±0.4050.4±52.6
CA47.0±94.5NS8.3±4.3NS0.60±1.80NS38.4±25.2NS
AA117.2±176.3NS24.5+90.20.0440.10±0.50NS43.3±59.2NS
FCGR2A rs1801274
RR110.3±182.96.4+4.60.01±0.0263.7±57.2
RH68.2+118.9NS19.1+65.7NS0.40±1.50NS41.3±22.1NS
HH55.7+86.8NS6.9±4.8NS0.10±0.50NS31.3±23.00.015

Distribution of VDR rs7975232 polymorphism genotypes and alleles in autoimmune thyroid disease patients according to clinical parameters_

GenderAgeAnti-Tg AntibodiesAnti-TPO Antibodies
Genotypes/ AllelesFn(%)Mn(%)P<40n(%)≥40n(%)P[-]n(%)[+]n(%)P[-]n(%)[+]n(%)P
CC CA46(32.0) 58(40.2)3 (16.7) 11 (61.1)NS8(19.0) 17(40.5)41 (34.2) 52(43.3)NS18(41.0) 17(38.6)12(26.7) 15 (33.3)NS13 (34.2) 14(36.8)18(37.6) 15 (31.2)NS
AA40(27.8)4(22.2)NS17(40.5)27(22.5)p 0.02; (𝜒2:4.79) OR: 3.22; 95% CI: 1.22-8.519(20.4)18(40.0)NS11 (29.0)15(31.2)NS
CA+AA

Dominant model.

98(68.0)15 (83.3)NS34(81.0)79(65.8)NS26(59.0)33 (73.3)NS25 (65.8)30(62.5)NS
C150(52.0)17(47.2)33 (39.3)134(55.8)53 (60.2)39(43.3)40(52.6)51(53.1)
A138(48.0)19(52.8)NS51 (60.7)106(44.2)p 0.01; (𝜒2:6.17) OR: 1.95; 95% CI: 1.17-3.2435(39.8)51 (56.7)p 0.03; (𝜒2:4.43); OR: 1.98; 95% CI: 1.09-3.5936(47.4)45 (46.9)NS

Distribution of VDR rs7975232 polymorphism genotypes and alleles in Graves’ disease patients according to clinical parameters_

GenderAgeAnti-Tg AntibodiesAnti-TPO Antibodies
Genotypes/ AllelesFn(%)Mn(%)P<40n(%)≥40n(%)P[-]n(%)[+]n(%)P[-]n(%)[+]n(%)P
CC17(37.8)2(18.2)3 (20.0)16(39.0)7(53.9)3 (21.4)6(42.8)5(38.5)
CA13 (28.9)7(63.6)NS3 (20.0)17(41.5)NS4(30.7)5 (35.7)NS4(28.6)5 (38.5)NS
AA15 (33.3)2(18.2)NS9(60.0)8 (19.5)p95

Fisher’s exact test.

: 0.03% CI; :OR: 1.26-6.0028.49 ;
2(15.4)6(42.9)NS4(28.6)3 (23.0)NS
CA+AA

Dominant model.

28(62.2)9(81.8)NS12(80.0)25(61.0)NS6(46.1)11 (78.6)NS8(57.2)8(61.5)NS
C47(52.2)11 (50.0)9(30.0)49 (59.8)18(69.2)11 (39.3)16(57.1)15 (57.7)
A43 (47.8)11 (50.0)NS21 (70.0)33 (40.2)p. 0.009; (𝜒2:6.64); OR: 3.46; 95% CI: 1.41-8.498(30.8)17(60.7)p 0.05; (𝜒2:3.73); OR: 3.47; 95% CI: 1.12-10.7212(42.9)11 (42.3)NS

Distribution of FCGR2A rs1801274 polymorphism genotypes and alleles in healthy controls (n = 162), autoimmune thyroid disease patients (n = 162), Hashimoto’s thyroiditis patients (n = 106) and Graves’ disease patients (n = 56)_

ControlsAITD PatientsHI PatientsGD Patients
Genotypes/ Allelesn(%)n(%)p(𝜒2)OR (95% CI)n(%)p(𝜒2)OR (95% CI)n(%)p(𝜒2)OR (95% CI)
RR62(38.3)43 (26.6)reference24 (22.6)reference19(34.0)reference
RH73 (45.0)78(48.1)0.11 (2.43)1.54(0.93-2.54)57(53.8)0.026 (4.95)2.01 (1.12-3.62)21 (37.5)0.99(0.00)0.93 (0.46-1.90)
HH27(16.7)41 (25.3)0.019(5.43)2.18 (1.17-4.07)25(23.6)0.026(4.91)2.39 (1.16-4.91)16(28.5)0.15 (1.98)1.93 (0.86-4.34)
RH+HH

Dominant model.

100(61.7)119(73.4)0.030(4.56)1.71 (1.07-2.74)82 (77.4)0.01 (6.48)2.11 (1.21-3.68)37(66.0)0.67(0.17)1.20(0.63-2.28)
R197(60.8)164(50.6)reference105(49.5)reference59(52.7)reference
H127(39.2)160(49.4)0.011 (6.40)1.51 (1.10-2.06)107(50.5)0.012(6.17)1.58(1.11-2.24)53 (47.3)0.16(1.94)1.39(0.90-2.14)

Distribution of FCGR2A rs1801274 polymorphism genotypes and alleles in Hashimoto’s thyroiditis patients according to clinical parameters_

GenderAgeAnti-Tg AntibodiesAnti-TPO Antibodies
Genotypes/ AllelesFn(%)Mn(%)P<40n(%)≥40n(%)P[-]n(%)[+]n(%)P[-]n(%)[+]n(%)P
RR24(24.3)0(0.0)6(22.3)18(22.8)6(19.3)6(19.3)5(20.8)6(17.1)
RH54(54.5)3 (42.9)NS16(59.2)41 (51.9)NS15 (48.4)17(54.9)NS12 (50.0)19(54.3)NS
HH21 (21.2)4(57.1)NS5(18.5)20(25.3)NS10 (32.3)8(25.8)NS7(29.2)10(28.6)NS
RH+HH

Dominant model.

75(75.7)7(1.0)NS21 (77.7)61 (77.2)NS25 (80.7)25(80.7)NS19(79.2)29(82.9)NS
R102(51.5)3(21.4)28(51.8)77(48.7)27(43.5)29(46.8)22(45.8)31 (44.3)
H96(48.5)11 (78.6)p

Fisher’s exact test.

: 0.04; OR: 0.25; 95% CI: 0.06-0.94
26(48.2)81 (51.3)NS35 (56.5)33 (53.2)NS26(54.2)39(55.7)NS
Language: English
Page range: 69 - 76
Published on: Aug 26, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2020 S Mestiri, I Zaaber, I Nasr, H Marmouch, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.